Pharma Thriller: Lilly Rumored To Be Mystery Bidder For ImClone
Executive Summary
Eli Lilly is rumored to be the mystery bidder for ImClone - the latest wrinkle in an ongoing saga that pits the biotech's Chairman Carl Icahn against its marketing partner Bristol-Myers Squibb. Lilly is reportedly offering $6.1 billion for the biotech, or $70 a share, which, if true, validates Icahn's hard-line rejection of a standing offer from BMS to pay $62 a share
You may also be interested in...
Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures
Eli Lilly announced Oct. 6 that it is acquiring ImClone for $6.5 billion, confirming rumors that had been circulating since the middle of the previous week. The central question now is whether Lilly can turn the buyout into a win for shareholders
Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures
Eli Lilly announced Oct. 6 that it is acquiring ImClone for $6.5 billion, confirming rumors that had been circulating since the middle of the previous week. The central question now is whether Lilly can turn the buyout into a win for shareholders
Lilly Prasugrel Review Extended: Why No News May Be Good News
Platelet drug deadline slips, but analysis by The RPM Report suggests that may be a sign of a positive outcome.